{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T13:04:16Z","timestamp":1781528656695,"version":"3.54.1"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,8,4]],"date-time":"2023-08-04T00:00:00Z","timestamp":1691107200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,8,4]],"date-time":"2023-08-04T00:00:00Z","timestamp":1691107200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Objectives<\/jats:title>\n                <jats:p>The HFA-PEFF score has been validated to hold great diagnostic and prognostic utility for heart failure with preserved ejection fraction (HFpEF). Idiopathic inflammatory myopathy (IIM) is recognized as one of the potential etiologies underlying HFpEF. Here, we intended to investigate the real prevalence of HFpEF in IIM via the HFA-PEFF score and explore the prognostic value of this score.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Two hundred twenty IIM patients were enrolled for assessment. The cohort was divided into low, intermediate and high tertiles of the HFA-PEFF score. Spearman\u2019s correlation analysis was used to explore the association between the score and disease activity. Chi-square test was applied to investigate the distribution discrepancy of HFA-PEFF tertiles among patients with different myositis-specific antibodies (MSAs) or myositis-associated antibodies (MAAs). Univariate and multivariate ordinal regression analyses were performed to screen risk factors for high HFA-PEFF scores. Survival curves were obtained using the Kaplan\u2013Meier method and log-rank tests.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>In total, 79 (35.9%), 107 (48.6%) and 34 (15.5%) patients were rated low, intermediate and high probability of HFpEF, respectively. The HFA-PEFF score correlated well with disease activity. Patients with positive AMA-M2 scored higher in the HFA-PEFF score (<jats:italic>p<\/jats:italic>\u2009=\u20090.011). During follow-up, patients with positive AMA-M2 or anti-SRP antibody developed an inclination towards concentric hypertrophy on echocardiography. Additionally, palpitation symptom, AMA-M2 positivity and elevated serum levels of LDH, cTnI were independent risk factors for high HFA-PEFF scores. Finally, a high-tertile HFA-PEFF score was related to lower overall survival rate (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001). Patients with positive AMA-M2 had poorer outcomes (<jats:italic>p<\/jats:italic>\u2009=\u20090.002).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>HFpEF was prevailing in IIM patients according to the HFA-PEFF score. The HFA-PEFF score correlated well with disease activity and held significant prognostic value. Patients with AMA-M2 antibody were prone to have poor outcomes.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13075-023-03131-6","type":"journal-article","created":{"date-parts":[[2023,8,4]],"date-time":"2023-08-04T08:02:22Z","timestamp":1691136142000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Value of the HFA-PEFF diagnostic algorithms for heart failure with preserved ejection fraction to the inflammatory myopathy population"],"prefix":"10.1186","volume":"25","author":[{"given":"Yunjing","family":"Shi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeping","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanjia","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiuxiu","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huihui","family":"Chi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tienan","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Honglei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaobing","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junna","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiongyi","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuochao","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianfen","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jialin","family":"Teng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengde","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutong","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,8,4]]},"reference":[{"issue":"12","key":"3131_CR1","doi-asserted-by":"publisher","first-page":"1955","DOI":"10.1136\/annrheumdis-2017-211468","volume":"76","author":"IE Lundberg","year":"2017","unstructured":"Lundberg IE, Tjarnlund A, Bottai M, et al. 2017 European League Against Rheumatism\/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. Ann Rheum Dis. 2017;76(12):1955\u201364.","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"3131_CR2","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.autrev.2018.09.008","volume":"18","author":"C Anquetil","year":"2019","unstructured":"Anquetil C, Boyer O, Wesner N, Benveniste O, Allenbach Y. Myositis-specific autoantibodies, a cornerstone in immune-mediated necrotizing myopathy. Autoimmun Rev. 2019;18(3):223\u201330.","journal-title":"Autoimmun Rev"},{"issue":"1","key":"3131_CR3","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1038\/s41572-021-00321-x","volume":"7","author":"IE Lundberg","year":"2021","unstructured":"Lundberg IE, Fujimoto M, Vencovsky J, et al. Idiopathic inflammatory myopathies. Nat Rev Dis Primers. 2021;7(1):86.","journal-title":"Nat Rev Dis Primers"},{"key":"3131_CR4","doi-asserted-by":"crossref","unstructured":"Wen L, Chen X, Cheng Q, et al. Myositis-specific autoantibodies and their clinical associations in idiopathic inflammatory myopathies: results from a cohort from China. Clin Rheumatol. 2022;41(11):3419\u201327.","DOI":"10.1007\/s10067-022-06291-z"},{"key":"3131_CR5","doi-asserted-by":"crossref","unstructured":"Jiang W, Shi J, Yang H, et al. The long-term outcome and prognosis factor of patients with idiopathic inflammatory myopathies based on myositis-specific autoantibodies. Arthritis Care Res (Hoboken). 2022;75(5):1175\u201382.","DOI":"10.1002\/acr.24993"},{"issue":"12","key":"3131_CR6","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1038\/s41584-020-00515-9","volume":"16","author":"Y Allenbach","year":"2020","unstructured":"Allenbach Y, Benveniste O, Stenzel W, Boyer O. Immune-mediated necrotizing myopathy: clinical features and pathogenesis. Nat Rev Rheumatol. 2020;16(12):689\u2013701.","journal-title":"Nat Rev Rheumatol"},{"issue":"1","key":"3131_CR7","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1186\/s13075-022-02906-7","volume":"24","author":"A Peter","year":"2022","unstructured":"Peter A, Balogh A, Csanadi Z, Danko K, Griger Z. Subclinical systolic and diastolic myocardial dysfunction in polyphasic polymyositis\/dermatomyositis: a 2-year longitudinal study. Arthritis Res Ther. 2022;24(1):219.","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"3131_CR8","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1007\/s10741-019-09909-8","volume":"26","author":"AH Opinc","year":"2021","unstructured":"Opinc AH, Makowski MA, Lukasik ZM, Makowska JS. Cardiovascular complications in patients with idiopathic inflammatory myopathies: does heart matter in idiopathic inflammatory myopathies? Heart Fail Rev. 2021;26(1):111\u201325.","journal-title":"Heart Fail Rev"},{"issue":"3","key":"3131_CR9","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1007\/s11926-012-0249-3","volume":"14","author":"I Marie","year":"2012","unstructured":"Marie I. Morbidity and mortality in adult polymyositis and dermatomyositis. Curr Rheumatol Rep. 2012;14(3):275\u201385.","journal-title":"Curr Rheumatol Rep"},{"issue":"11","key":"3131_CR10","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1161\/CIRCRESAHA.119.313572","volume":"124","author":"MA Pfeffer","year":"2019","unstructured":"Pfeffer MA, Shah AM, Borlaug BA. Heart Failure With Preserved Ejection Fraction In Perspective. Circ Res. 2019;124(11):1598\u2013617.","journal-title":"Circ Res"},{"issue":"40","key":"3131_CR11","doi-asserted-by":"publisher","first-page":"3297","DOI":"10.1093\/eurheartj\/ehz641","volume":"40","author":"B Pieske","year":"2019","unstructured":"Pieske B, Tschope C, de Boer RA, et al. How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). Eur Heart J. 2019;40(40):3297\u2013317.","journal-title":"Eur Heart J"},{"issue":"1 Pt 2","key":"3131_CR12","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.jcmg.2019.02.031","volume":"13","author":"MA Chamsi-Pasha","year":"2020","unstructured":"Chamsi-Pasha MA, Zhan Y, Debs D, Shah DJ. CMR in the Evaluation of Diastolic Dysfunction and Phenotyping of HFpEF: Current Role and Future Perspectives. JACC Cardiovasc Imaging. 2020;13(1 Pt 2):283\u201396.","journal-title":"JACC Cardiovasc Imaging"},{"issue":"19","key":"3131_CR13","doi-asserted-by":"publisher","first-page":"1868","DOI":"10.1056\/NEJMcp1511175","volume":"375","author":"MM Redfield","year":"2016","unstructured":"Redfield MM. Heart Failure with Preserved Ejection Fraction. N Engl J Med. 2016;375(19):1868\u201377.","journal-title":"N Engl J Med"},{"issue":"10","key":"3131_CR14","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1016\/j.jacc.2018.01.016","volume":"71","author":"NL Pereira","year":"2018","unstructured":"Pereira NL, Grogan M, Dec GW. Spectrum of Restrictive and Infiltrative Cardiomyopathies: Part 1 of a 2-Part Series. J Am Coll Cardiol. 2018;71(10):1130\u201348.","journal-title":"J Am Coll Cardiol"},{"issue":"10","key":"3131_CR15","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.119.014661","volume":"9","author":"MJ Ahlers","year":"2020","unstructured":"Ahlers MJ, Lowery BD, Farber-Eger E, et al. Heart Failure Risk Associated With Rheumatoid Arthritis-Related Chronic Inflammation. J Am Heart Assoc. 2020;9(10): e014661.","journal-title":"J Am Heart Assoc"},{"key":"3131_CR16","doi-asserted-by":"publisher","first-page":"iv18","DOI":"10.1093\/rheumatology\/kel311","volume":"45 Suppl 4","author":"IE Lundberg","year":"2006","unstructured":"Lundberg IE. The heart in dermatomyositis and polymyositis. Rheumatology (Oxford). 2006;45 Suppl 4:iv18-21.","journal-title":"Rheumatology (Oxford)."},{"issue":"1","key":"3131_CR17","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1093\/rheumatology\/keab573","volume":"61","author":"JL Fairley","year":"2021","unstructured":"Fairley JL, Wicks I, Peters S, Day J. Defining cardiac involvement in idiopathic inflammatory myopathies: a systematic review. Rheumatology (Oxford). 2021;61(1):103\u201320.","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"3131_CR18","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1002\/ejhf.1614","volume":"22","author":"A Barandiaran Aizpurua","year":"2020","unstructured":"Barandiaran Aizpurua A, Sanders-van Wijk S, Brunner-La Rocca HP, et al. Validation of the HFA-PEFF score for the diagnosis of heart failure with preserved ejection fraction. Eur J Heart Fail. 2020;22(3):413\u201321.","journal-title":"Eur J Heart Fail"},{"key":"3131_CR19","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.ijcard.2021.08.001","volume":"342","author":"A Tada","year":"2021","unstructured":"Tada A, Nagai T, Omote K, et al. Performance of the H(2)FPEF and the HFA-PEFF scores for the diagnosis of heart failure with preserved ejection fraction in Japanese patients: A report from the Japanese multicenter registry. Int J Cardiol. 2021;342:43\u20138.","journal-title":"Int J Cardiol"},{"issue":"5","key":"3131_CR20","doi-asserted-by":"publisher","first-page":"3603","DOI":"10.1002\/ehf2.13532","volume":"8","author":"J Nikorowitsch","year":"2021","unstructured":"Nikorowitsch J, Bei der Kellen R, Kirchhof P, et al. Applying the ESC 2016, H(2) FPEF, and HFA-PEFF diagnostic algorithms for heart failure with preserved ejection fraction to the general population. ESC Heart Fail. 2021;8(5):3603\u201312.","journal-title":"ESC Heart Fail."},{"issue":"5","key":"3131_CR21","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1253\/circj.CJ-20-0784","volume":"85","author":"Y Seo","year":"2021","unstructured":"Seo Y, Ishizu T, Ieda M, Ohte N, Investigators JLS. Clinical Usefulness of the HFA-PEFF Diagnostic Scoring System in Identifying Late Elderly Heart Failure With Preserved Ejection Fraction Patients. Circ J. 2021;85(5):604\u201311.","journal-title":"Circ J"},{"key":"3131_CR22","doi-asserted-by":"crossref","unstructured":"Tomasoni D, Aimo A, Merlo M, et al. Value of the HFA-PEFF and H2 FPEF scores in patients with heart failure and preserved ejection fraction caused by cardiac amyloidosis. Eur J Heart Fail. 2022;24(12):2374\u201386.","DOI":"10.1002\/ejhf.2616"},{"key":"3131_CR23","doi-asserted-by":"crossref","unstructured":"Hashemi D, Mende M, Trippel TD, et al. Evaluation of the HFA-PEFF Score: results from the prospective DIAST-CHF cohort. ESC Heart Fail. 2022;9(6):4120\u201328.","DOI":"10.1002\/ehf2.14131"},{"issue":"8","key":"3131_CR24","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1016\/j.jchf.2020.03.013","volume":"8","author":"S Selvaraj","year":"2020","unstructured":"Selvaraj S, Myhre PL, Vaduganathan M, et al. Application of Diagnostic Algorithms for Heart Failure With Preserved Ejection Fraction to the Community. JACC Heart Fail. 2020;8(8):640\u201353.","journal-title":"JACC Heart Fail"},{"issue":"7","key":"3131_CR25","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1056\/NEJM197502132920706","volume":"292","author":"A Bohan","year":"1975","unstructured":"Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med. 1975;292(7):344\u20137.","journal-title":"N Engl J Med"},{"issue":"5","key":"3131_CR26","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.nmd.2004.02.006","volume":"14","author":"JE Hoogendijk","year":"2004","unstructured":"Hoogendijk JE, Amato AA, Lecky BR, et al. 119th ENMC international workshop: trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10\u201312 October 2003, Naarden. The Netherlands Neuromuscul Disord. 2004;14(5):337\u201345.","journal-title":"The Netherlands Neuromuscul Disord"},{"issue":"5","key":"3131_CR27","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1136\/annrheumdis-2017-211400","volume":"76","author":"R Aggarwal","year":"2017","unstructured":"Aggarwal R, Rider LG, Ruperto N, et al. 2016 American College of Rheumatology\/European League Against Rheumatism criteria for minimal, moderate, and major clinical response in adult dermatomyositis and polymyositis: An International Myositis Assessment and Clinical Studies Group\/Paediatric Rheumatology International Trials Organisation Collaborative Initiative. Ann Rheum Dis. 2017;76(5):792\u2013801.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"3131_CR28","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1038\/s41569-020-00480-6","volume":"18","author":"S Mishra","year":"2021","unstructured":"Mishra S, Kass DA. Cellular and molecular pathobiology of heart failure with preserved ejection fraction. Nat Rev Cardiol. 2021;18(6):400\u201323.","journal-title":"Nat Rev Cardiol"},{"issue":"4","key":"3131_CR29","first-page":"313","volume":"39","author":"F Prisco","year":"2020","unstructured":"Prisco F, Papparella S, Paciello O. The correlation between cardiac and skeletal muscle pathology in animal models of idiopathic inflammatory myopathies. Acta Myol. 2020;39(4):313\u20139.","journal-title":"Acta Myol"},{"issue":"1","key":"3131_CR30","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s12968-018-0430-6","volume":"20","author":"AT Huber","year":"2018","unstructured":"Huber AT, Bravetti M, Lamy J, et al. Non-invasive differentiation of idiopathic inflammatory myopathy with cardiac involvement from acute viral myocarditis using cardiovascular magnetic resonance imaging T1 and T2 mapping. J Cardiovasc Magn Reson. 2018;20(1):11.","journal-title":"J Cardiovasc Magn Reson"},{"issue":"1","key":"3131_CR31","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s12968-020-00616-0","volume":"22","author":"Y Xu","year":"2020","unstructured":"Xu Y, Sun J, Wan K, et al. Multiparametric cardiovascular magnetic resonance characteristics and dynamic changes in myocardial and skeletal muscles in idiopathic inflammatory cardiomyopathy. J Cardiovasc Magn Reson. 2020;22(1):22.","journal-title":"J Cardiovasc Magn Reson"},{"issue":"10","key":"3131_CR32","doi-asserted-by":"publisher","first-page":"5139","DOI":"10.1007\/s00330-019-06054-6","volume":"29","author":"AT Huber","year":"2019","unstructured":"Huber AT, Lamy J, Bravetti M, et al. Comparison of MR T1 and T2 mapping parameters to characterize myocardial and skeletal muscle involvement in systemic idiopathic inflammatory myopathy (IIM). Eur Radiol. 2019;29(10):5139\u201347.","journal-title":"Eur Radiol"},{"issue":"3","key":"3131_CR33","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.ijcard.2010.08.013","volume":"148","author":"R Gupta","year":"2011","unstructured":"Gupta R, Wayangankar SA, Targoff IN, Hennebry TA. Clinical cardiac involvement in idiopathic inflammatory myopathies: a systematic review. Int J Cardiol. 2011;148(3):261\u201370.","journal-title":"Int J Cardiol"},{"key":"3131_CR34","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s13023-015-0277-y","volume":"10","author":"S Suzuki","year":"2015","unstructured":"Suzuki S, Nishikawa A, Kuwana M, et al. Inflammatory myopathy with anti-signal recognition particle antibodies: case series of 100 patients. Orphanet J Rare Dis. 2015;10:61.","journal-title":"Orphanet J Rare Dis"},{"key":"3131_CR35","doi-asserted-by":"crossref","unstructured":"Colapietro F, Lleo A, Generali E. Antimitochondrial Antibodies: from Bench to Bedside. Clin Rev Allergy Immunol. 2021;63(2):166\u201377.","DOI":"10.1007\/s12016-021-08904-y"},{"issue":"Pt 6","key":"3131_CR36","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1093\/brain\/aws106","volume":"135","author":"MH Maeda","year":"2012","unstructured":"Maeda MH, Tsuji S, Shimizu J. Inflammatory myopathies associated with anti-mitochondrial antibodies. Brain. 2012;135(Pt 6):1767\u201377.","journal-title":"Brain"},{"issue":"11","key":"3131_CR37","doi-asserted-by":"publisher","first-page":"4597","DOI":"10.1007\/s10067-021-05828-y","volume":"40","author":"L Zhang","year":"2021","unstructured":"Zhang L, Zhu H, Yang P, et al. Myocardial involvement in idiopathic inflammatory myopathies: a multi-center cross-sectional study in the CRDC-MYO Registry. Clin Rheumatol. 2021;40(11):4597\u2013608.","journal-title":"Clin Rheumatol"},{"issue":"4","key":"3131_CR38","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1016\/j.semarthrit.2017.06.004","volume":"47","author":"J Albayda","year":"2018","unstructured":"Albayda J, Khan A, Casciola-Rosen L, Corse AM, Paik JJ, Christopher-Stine L. Inflammatory myopathy associated with anti-mitochondrial antibodies: A distinct phenotype with cardiac involvement. Semin Arthritis Rheum. 2018;47(4):552\u20136.","journal-title":"Semin Arthritis Rheum"},{"issue":"1","key":"3131_CR39","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1136\/annrheumdis-2018-213518","volume":"78","author":"C Bergua","year":"2019","unstructured":"Bergua C, Chiavelli H, Allenbach Y, et al. In vivo pathogenicity of IgG from patients with anti-SRP or anti-HMGCR autoantibodies in immune-mediated necrotising myopathy. Ann Rheum Dis. 2019;78(1):131\u20139.","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"3131_CR40","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1136\/annrheumdis-2011-200414","volume":"71","author":"A Ambrosi","year":"2012","unstructured":"Ambrosi A, Dzikaite V, Park J, et al. Anti-Ro52 monoclonal antibodies specific for amino acid 200\u2013239, but not other Ro52 epitopes, induce congenital heart block in a rat model. Ann Rheum Dis. 2012;71(3):448\u201354.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"3131_CR41","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1097\/MEG.0000000000002472","volume":"35","author":"Y Dimitroglou","year":"2023","unstructured":"Dimitroglou Y, Tsartsalis D, Vasilieva L, et al. HFA-PEFF score as an independent predictor of 2-year mortality in liver cirrhosis patients. Eur J Gastroenterol Hepatol. 2023;35(2):204\u201311.","journal-title":"Eur J Gastroenterol Hepatol"}],"container-title":["Arthritis Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-023-03131-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13075-023-03131-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-023-03131-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,17]],"date-time":"2023-11-17T20:07:07Z","timestamp":1700251627000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-023-03131-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,4]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["3131"],"URL":"https:\/\/doi.org\/10.1186\/s13075-023-03131-6","relation":{},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,4]]},"assertion":[{"value":"7 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 August 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was performed in accordance with the Declaration of Helsinki and the Principles of Good Clinical Practice. Biological samples were obtained under a protocol approved by the Institutional Research Ethics Committee of Ruijin Hospital (ID: 2016\u201362), Shanghai, China. All subjects gave written informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All participants and authors gave their consent for publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"141"}}